RenDong Medicine and Sweden's Prostatype Genomics Launch Commercial Partnership for Prostatype® in China
[October 15, 2020, Shanghai] Rendo Medical Technology Co., Ltd. (hereinafter referred to as “Rendo Medical”) and Prostatype Genomics AB of Sweden (hereinafter referred to as “Prostatype Genomics”) have officially signed a contract to launch Prostatype®The commercialization process in mainland China.
Rendong Medicine is China’s leading provider of comprehensive genetic testing solutions and the market leader in precision diagnostics for urological tumors in China. Prostatype Genomics, a company incubated at the Karolinska Institutet in Sweden, has dedicated itself to product research and development for fifteen years and pioneered a genetic testing system for risk assessment in the diagnosis and prognosis of prostate cancer. This collaboration begins in the field of prostate cancer diagnosis, enabling more accurate screening for individuals at low, moderate, and high risk in the early stages. It aims to assist urologists in providing more scientifically grounded treatment options for prostate cancer patients, thereby delivering better care and support to patients.
Ms. Jin Ge, CEO of Rendong Medicine“The collaboration with Prostatype Genomics represents one of Rendong Medicine’s strategic priorities, grounded in a global perspective and focused on deepening expertise in the vertical specialty of urologic oncology to prepare for the future. This partnership enriches Rendong Medicine’s product portfolio in the field of urologic cancers, enabling precise testing and dynamic monitoring of disease progression for prostate cancer patients in China, thereby contributing to the achievement of the cancer prevention and control goals outlined in the Healthy China 2030 initiative.”
Fredrik Persson, CEO of Prostatype Genomics, Swedenstated: “This strategic collaboration with RenDong Medical represents a significant initiative for our corporate development and product promotion. China is a critical component of Prostatype Genomics’ global market strategy, and as a leader in precision diagnostics for urologic oncology in China, RenDong Medical is a highly valued partner. We are confident that Prostatype”®“...to facilitate precision treatment for prostate cancer patients in China in the near future.”
Prostatype®（Prostatype®or PrTS®) is a CE-certified IVD product that provides reliable prognostic assessment for newly diagnosed prostate cancer patients. Prostatype®PrTS: A globally leading prognostic risk assessment system for prostate cancer genetic testing, which integrates tumor cell gene expression data with clinical parameters (PSA, Gleason score, and tumor stage) to comprehensively evaluate tumor aggressiveness and the risk of prostate cancer-specific mortality.®Providing clinical decision support for patients and physicians to reduce the risk of overtreatment or undertreatment can alleviate the growing economic burden that prostate cancer treatment places on the healthcare system.
Rendong Medicine was established in December 2015. As a leading provider of comprehensive genetic testing solutions in China, it is also the market leader in genetic testing for urological tumors. Centered on next-generation sequencing (NGS) technology and leveraging tumor immuno-multi-omics, the company focuses on specific cancer types to develop integrated diagnostic and therapeutic solutions.
In 2017, we pioneered the “Ten-Thousand-Patient Tumor Immunity Ark Program” in China and launched the country’s first ctDNA panel for precision immuno-oncology therapy and treatment response assessment. Our product portfolio now covers the entire continuum of precision oncology care, including precision immunotherapy, medication guidance, and prognosis prevention. Among these, Pushengtai®- The 66-gene precision diagnosis and treatment testing product for prostate cancer, UroSure™—the gene testing product for precision diagnosis and treatment of urothelial carcinoma, and RenShiAn Selected™—the 77-gene precision diagnosis and treatment testing product for renal cell carcinoma have become well-known brands in their respective niche oncology segments. Additionally, the company has related products and R&D layouts for breast cancer, colorectal cancer, head and neck squamous cell carcinoma, and other tumor types. Rendong Medicine has currently initiated the construction of an IVD manufacturing facility and new office spaces in Suzhou, and successfully secured strategic financing in Series A and Pre-Series B rounds from the capital market in 2018 and 2020, respectively.
The company was established in 2007 as a startup successfully spun out from the Karolinska Institutet in Sweden. The Karolinska Institutet is one of the most prestigious medical universities in Europe and worldwide, and its Nobel Assembly has been responsible for selecting the laureates of the Nobel Prize in Physiology or Medicine since 1901. The company was spun off from the institute with the aim of translating research findings into clinical applications, and it has successfully developed Prostatype, which has received CE certification.®Test system. Prostatype Genomics is the exclusive owner of all research and development, intellectual property rights, and patents. The company has filed patent applications in Sweden, the United States, mainland China, Hong Kong, Japan, and Europe (EPO), with validity until 2034. Patent applications in Canada are currently pending. Prostatype®is a registered trademark in Europe.
Prostatype Genomics envisions a future where physicians and patients have full confidence in their treatment decisions following a prostate cancer diagnosis. Prostatype Genomics is committed to transforming the lives of prostate cancer patients by guiding treatment decisions through the discovery and commercialization of translational assays, thereby improving patients’ quality of life while reducing healthcare costs. Prostatype Genomics will achieve this by enabling Prostatype®To achieve this goal, it has become a global testing system for patients newly diagnosed with prostate cancer. The company will be listed on the Nasdaq First North Growth Market, with trading of its shares and warrants expected to commence on Tuesday, October 27, 2020.
